Cencora raises long-term EPS growth outlook to 9%-13% as company accelerates specialty focus

Q4 2025 Management View Robert Mauch, President and CEO, highlighted that "Cencora achieved strong financial performance with adjusted operating income and adjusted diluted EPS growth of 16%, driven ...

Qiagen signals $2.38 adjusted EPS target and $500M share repurchase while advancing single ...

Q3 2025 Management View CEO Thierry Bernard opened the call highlighting, "the 24th consecutive quarter in which we met or ...